Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database
- PMID: 15904508
- PMCID: PMC1164404
- DOI: 10.1186/1471-2407-5-48
Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database
Abstract
Background: The present commonly used five-year survival rates are not adequate to represent the statistical cure. In the present study, we established the minimum number of years required for follow-up to estimate statistical cure rate, by using a lognormal distribution of the survival time of those who died of their cancer. We introduced the term, threshold year, the follow-up time for patients dying from the specific cancer covers most of the survival data, leaving less than 2.25% uncovered. This is close enough to cure from that specific cancer.
Methods: Data from the Surveillance, Epidemiology and End Results (SEER) database were tested if the survival times of cancer patients who died of their disease followed the lognormal distribution using a minimum chi-square method. Patients diagnosed from 1973-1992 in the registries of Connecticut and Detroit were chosen so that a maximum of 27 years was allowed for follow-up to 1999. A total of 49 specific organ sites were tested. The parameters of those lognormal distributions were found for each cancer site. The cancer-specific survival rates at the threshold years were compared with the longest available Kaplan-Meier survival estimates.
Results: The characteristics of the cancer-specific survival times of cancer patients who died of their disease from 42 cancer sites out of 49 sites were verified to follow different lognormal distributions. The threshold years validated for statistical cure varied for different cancer sites, from 2.6 years for pancreas cancer to 25.2 years for cancer of salivary gland. At the threshold year, the statistical cure rates estimated for 40 cancer sites were found to match the actuarial long-term survival rates estimated by the Kaplan-Meier method within six percentage points. For two cancer sites: breast and thyroid, the threshold years were so long that the cancer-specific survival rates could yet not be obtained because the SEER data do not provide sufficiently long follow-up.
Conclusion: The present study suggests a certain threshold year is required to wait before the statistical cure rate can be estimated for each cancer site. For some cancers, such as breast and thyroid, the 5- or 10-year survival rates inadequately reflect statistical cure rates, and highlight the need for long-term follow-up of these patients.
Figures


Similar articles
-
Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.BMC Cancer. 2004 Sep 2;4:60. doi: 10.1186/1471-2407-4-60. BMC Cancer. 2004. PMID: 15345027 Free PMC article.
-
Long-term survival rates of laryngeal cancer patients treated by radiation and surgery, radiation alone, and surgery alone: studied by lognormal and Kaplan-Meier survival methods.BMC Cancer. 2005 Jan 31;5:13. doi: 10.1186/1471-2407-5-13. BMC Cancer. 2005. PMID: 15683543 Free PMC article.
-
Cure fraction estimation from the mixture cure models for grouped survival data.Stat Med. 2004 Jun 15;23(11):1733-47. doi: 10.1002/sim.1774. Stat Med. 2004. PMID: 15160405
-
Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.Breast Cancer. 2012 Jul;19(3):218-37. doi: 10.1007/s12282-012-0347-0. Epub 2012 Apr 25. Breast Cancer. 2012. PMID: 22532161 Review.
-
Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications.Eur J Cancer. 2004 Feb;40(3):326-35. doi: 10.1016/j.ejca.2003.10.013. Eur J Cancer. 2004. PMID: 14746849 Review.
Cited by
-
Programmed death‑ligand 1 expression in tumor cells and tumor‑infiltrating lymphocytes are associated with depth of tumor invasion in penile cancer.Biomed Rep. 2023 May 29;19(1):44. doi: 10.3892/br.2023.1627. eCollection 2023 Jul. Biomed Rep. 2023. PMID: 37324166 Free PMC article.
-
Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer.J Natl Cancer Inst Monogr. 2014 Nov;2014(49):244-54. doi: 10.1093/jncimonographs/lgu015. J Natl Cancer Inst Monogr. 2014. PMID: 25417238 Free PMC article.
-
FBXL6 degrades phosphorylated p53 to promote tumor growth.Cell Death Differ. 2021 Jul;28(7):2112-2125. doi: 10.1038/s41418-021-00739-6. Epub 2021 Feb 10. Cell Death Differ. 2021. PMID: 33568778 Free PMC article.
-
What is the Definition of Cure in Non-small Cell Lung Cancer?Oncol Ther. 2021 Dec;9(2):365-371. doi: 10.1007/s40487-021-00163-3. Epub 2021 Aug 10. Oncol Ther. 2021. PMID: 34374957 Free PMC article. Review.
-
A sup-score test for the cure fraction in mixture models for long-term survivors.Biometrics. 2016 Dec;72(4):1348-1357. doi: 10.1111/biom.12514. Epub 2016 Apr 14. Biometrics. 2016. PMID: 27078815 Free PMC article.
References
-
- Feinleib M, McMahon B. Variation in the duration of survival of patients with the chronic leukemias. Blood. 1960;15:332–349. - PubMed
-
- Kondo K. The log-normal distribution of the incubation time of exogenous diseases. Jpn J Hum Genet. 1977;21:217–237. - PubMed
-
- Magurran AE. Ecological diversity and its measurement. London, Croom Helm; 1988.
-
- Aitchison J, Brown JAC. The Log-normal distribution. Cambridge, UK, Cambridge University Press; 1957.
-
- Crow EL, Shimizu K. Log-normal distributions: Theory and application. New York, NY, Dekker; 1988.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources